-
Je něco špatně v tomto záznamu ?
Genetic analysis of the CYP21A2 gene in neonatal dried blood spots from children with transiently elevated 17-hydroxyprogesterone
J. Malikova, F. Votava, Z. Vrzalova, J. Lebl, O. Cinek,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NS9981
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
NLK
Wiley Online Library (archiv)
od 1997-01-01 do 2012-12-31
- MeSH
- 17-alfa-hydroxyprogesteron krev MeSH
- bodová mutace genetika MeSH
- genetické testování metody MeSH
- lidé MeSH
- novorozenec MeSH
- novorozenecký screening MeSH
- pseudogeny genetika MeSH
- steroid-21-hydroxylasa genetika MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- novorozenec MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: Neonatal screening for congenital adrenal hyperplasia (CAH) identifies a certain proportion of newborns with transient moderate elevation of 17-hydroxyprogesterone (17-OHP). These children require regular follow-up until normalization of their 17-OHP levels. We investigated the possibility of reducing the individuals' recall rates by using genetic methods on their original neonatal dried blood spots. PATIENTS AND METHODS: We analysed neonatal dried blood spots from 753 subjects with transiently elevated levels of 17-OHP. The CYP21A2 gene was sequenced to detect point mutations, and the presence of CYP21A2 was further confirmed by two methods utilizing the difference between CYP21A2 and its CYP21A1P pseudogene in the sequence of exon 3 (8-bp deletion). The accuracy of the methods was verified using samples from 70 subjects with known CYP21A2 mutations and 181 healthy children. RESULT: Among the 701 successfully sequenced samples from subjects with transiently elevated 17-OHP, 670 (95%) had no point mutations or novel variants in the CYP21A2 gene. We found no individuals carrying genotypes consistent with the diagnosis of CAH (i.e. homozygotes or compound heterozygotes for point mutations, large deletions or rearrangements). However, 21 heterozygous carriers of known point mutations that cause the classic and nonclassic forms of CAH were identified. Additionally, we detected eight heterozygous and two homozygous point variants with unknown functional significance. CONCLUSION: Although CAH caused by 21-hydroxylase deficiency could be genetically excluded with a reasonable degree of confidence in 95% of the genotyped subjects that had transiently elevated 17-OHP, the performance of the tests was suboptimal when performed using dried blood spots and time-consuming in comparison with the current practice of repeated measurements of 17-OHP. The introduction of this method into clinical practice seems to be impractical at this stage.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13000953
- 003
- CZ-PrNML
- 005
- 20141111122756.0
- 007
- ta
- 008
- 130108s2012 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/j.1365-2265.2012.04358.x $2 doi
- 035 __
- $a (PubMed)22313422
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Malikova, Jana $u Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
- 245 10
- $a Genetic analysis of the CYP21A2 gene in neonatal dried blood spots from children with transiently elevated 17-hydroxyprogesterone / $c J. Malikova, F. Votava, Z. Vrzalova, J. Lebl, O. Cinek,
- 520 9_
- $a BACKGROUND: Neonatal screening for congenital adrenal hyperplasia (CAH) identifies a certain proportion of newborns with transient moderate elevation of 17-hydroxyprogesterone (17-OHP). These children require regular follow-up until normalization of their 17-OHP levels. We investigated the possibility of reducing the individuals' recall rates by using genetic methods on their original neonatal dried blood spots. PATIENTS AND METHODS: We analysed neonatal dried blood spots from 753 subjects with transiently elevated levels of 17-OHP. The CYP21A2 gene was sequenced to detect point mutations, and the presence of CYP21A2 was further confirmed by two methods utilizing the difference between CYP21A2 and its CYP21A1P pseudogene in the sequence of exon 3 (8-bp deletion). The accuracy of the methods was verified using samples from 70 subjects with known CYP21A2 mutations and 181 healthy children. RESULT: Among the 701 successfully sequenced samples from subjects with transiently elevated 17-OHP, 670 (95%) had no point mutations or novel variants in the CYP21A2 gene. We found no individuals carrying genotypes consistent with the diagnosis of CAH (i.e. homozygotes or compound heterozygotes for point mutations, large deletions or rearrangements). However, 21 heterozygous carriers of known point mutations that cause the classic and nonclassic forms of CAH were identified. Additionally, we detected eight heterozygous and two homozygous point variants with unknown functional significance. CONCLUSION: Although CAH caused by 21-hydroxylase deficiency could be genetically excluded with a reasonable degree of confidence in 95% of the genotyped subjects that had transiently elevated 17-OHP, the performance of the tests was suboptimal when performed using dried blood spots and time-consuming in comparison with the current practice of repeated measurements of 17-OHP. The introduction of this method into clinical practice seems to be impractical at this stage.
- 650 _2
- $a 17-alfa-hydroxyprogesteron $x krev $7 D019326
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a genetické testování $x metody $7 D005820
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a novorozenec $7 D007231
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a novorozenecký screening $7 D015997
- 650 _2
- $a bodová mutace $x genetika $7 D017354
- 650 _2
- $a pseudogeny $x genetika $7 D011544
- 650 _2
- $a steroid-21-hydroxylasa $x genetika $7 D013255
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Votava, Felix
- 700 1_
- $a Vrzalova, Zuzana
- 700 1_
- $a Lebl, Jan
- 700 1_
- $a Cinek, Ondrej
- 773 0_
- $w MED00009474 $t Clinical endocrinology $x 1365-2265 $g Roč. 77, č. 2 (2012), s. 187-194
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22313422 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130108 $b ABA008
- 991 __
- $a 20141111122809 $b ABA008
- 999 __
- $a ok $b bmc $g 963735 $s 799117
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 77 $c 2 $d 187-194 $i 1365-2265 $m Clinical endocrinology $n Clin Endocrinol (Oxf) $x MED00009474
- GRA __
- $a NS9981 $p MZ0
- LZP __
- $a Pubmed-20130108